The Immunology Market is expected to reach USD 254.23 Billion by 2032 and grow at a CAGR of 11.8%.
The rising demand for biosimilars due to their similar efficacy and cheaper alternatives is significantly propelling the adoption of biosimilars in developed and developing regions. The higher cost of biologics hinders the availability and affordability of drugs for the patient population in developing regions. For example, Neulasta, a drug developed by Amgen to fight off infections for chemotherapy patients, costs over USD 10,000 per ml; whereas, its biosimilar, Ziexentzo, costs around USD 6500 per ml.